LB791 Avacopan, a highly selective small molecule inhibitor of c5a receptor, in patients with Hidradenitis Suppurativa: Initial results from a randomized, double-blind, placebo-controlled, phase 2 study (aurora)

Abstract

Hidradenitis suppurativa (HS) is a chronic, debilitating, inflammatory skin disorder. Neutrophils are prominent in nodules, abscesses, and tunnels. Complement C5a is a key source of inflammation promoting neutrophil recruitment, activation and localized inflammation in HS via the C5a receptor (C5aR). Current HS therapy with antibiotics, corticosteroids or TNF-α inhibitors is insufficient. Avacopan (CCX168) is an orally-administered inhibitor of C5aR (which leaves the beneficial actions of a second C5a pathway via CC5L2 intact) which was tested as a novel therapeutic approach in HS.